ArticleFrontiers in oncology2025
Computed tomography features and clinicopathological characteristics of resectable esophageal sarcomatoid carcinoma: a retrospective study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Esophageal sarcomatoid carcinoma (ESC) is a rare malignant tumor. This study aims to analyze the computed tomography (CT) features and clinicopathological characteristics of resectable ESC. Methods: The CT and clinicopathological data of 25 patients with ESC, confirmed by postoperative pathology, were retrospectively analyzed. The preoperative CT feature analysis included the average tumor CT attenuation value (CT Results: Among the 25 patients with ESC, 19 were male and 6 were female. The patients' ages ranged from 47 to 73 years, with a mean age of 65.48 ± 6.85 years and a median age of 68 years. The pathological staging results showed that 14 cases were at stage T1, 5 cases at stage T2, 5 cases at stage T3, and 1 case at stage T4. Lymph node metastasis was identified in 12 cases, including 5 classified as N1, 4 as N2, and 3 as N3. The pTT ranged from 0.50 to 4.00 cm, with a mean of 1.92 ± 1.02 cm and a median of 1.50 cm; the cTT ranged from 0.60 to 4.10 cm, with a mean of 2.02 ± 0.90 cm and a median of 1.66 cm. Bland-Altman analysis demonstrated a mean difference of 0.10 cm between cTT and pTT, with 92.0% (23/25) of cases lying within the 95% limits of agreement (Mean ± 1.96 SD). The Pearson correlation coefficient between the two measurements was 0.980, indicating a strong positive correlation. The pTL ranged from 2.00 to 7.00 cm, with a mean of 4.24 ± 1.50 cm and a median of 4.00 cm; the cTL ranged from 2.57 to 7.50 cm, with a mean of 4.41 ± 1.48 cm and a median of 4.16 cm. Bland-Altman analysis demonstrated a mean difference of 0.18 cm between cTL and pTL, with 92.0% (23/25) of cases lying within the 95% limits of agreement. The Pearson correlation coefficient was 0.884. The cTV ranged from 1.56 cm³ to 41.49 cm³, with a median of 8.25 cm³. Regarding tumor morphology, 20 cases presented as mass-forming type, while 5 were classified as wall-thickening type. Significant differences in both pTT and cTT were observed between the two morphological types; however, no statistically significant differences were found in other CT features. Conclusion: ESC is a rare malignant tumor characterized by distinctive CT features. The majority of cases manifest as the mass-forming type, while a smaller proportion present as the wall-thickening type. The definitive diagnosis of ESC depends on pathological examination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.